Insulin degrading enzyme emerges as a novel biomarker and therapeutic target in Multiple Myeloma.

Multiple Myeloma is a disease of plasma cells in bone marrow that represents 1% of all cancers and 15% of haematological malignancies.

The team of Benoit Deprez and his collaborators discloses in the British Journal of Pharmacology the discovery of Insulin Degrading Enzyme as a novel biomarker and a new molecular vulnerability in Multiple Myeloma. This study also demonstrates the relevance of IDE inhibitors as boosters of proteasome inhibitors to better treat patients with MM.This discovery was made possible by a long lasting collaboration with Jérôme Moreaux, (IGF Montpellier), France Elke de Bruyne (VUB Brussels, Belgium) and Wei Jen Tang (BenMay Department, Chicago, USA), and Peter van Endert (Institut Necker Enfants Malades, Paris).

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma
Laetitia Lesire, Rebecca Deprez-Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei-Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez
2026 , British Journal of Pharmacology. https://doi.org/10.1111/bph.70407

Drug Discovery Center
Université de Lille – Inserm – Institut Pasteur de Lille